ChemMedChem · 2015 · 40 citations · 17 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryPharmacodynamicsVirologyAntiviral AgentsAntiviral Drug ResistanceAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyViral InfectionsAntiviral TherapeuticsCapsid InhibitorsCommon ColdCoxsackievirus InfectionsCytochrome P450 Enzyme ActivityCytochrome P450 Enzyme InhibitionViral MyocarditisViral Therapeutic Targets
There are currently no drugs available for the treatment of enterovirus (EV)-induced acute and chronic diseases such as the common cold, meningitis, encephalitis, pneumonia, and myocarditis with or without consecutive dilated cardiomyopathy. Here, we report the discovery and characterization of pyrazolopyrimidines, a well-tolerated and potent class of novel EV inhibitors. The compounds inhibit the replication of a broad spectrum of EV in vitro with IC50 values between 0.04 and 0.64 μM for viruses resistant to pleconaril, a known capsid-binding inhibitor, without affecting cytochrome P450 enzyme activity. Using virological and genetics methods, the viral capsid was identified as the target of the most promising, orally bioavailable compound 3-(4-trifluoromethylphenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine (OBR-5-340). Its prophylactic as well as therapeutic application was proved for coxsackievirus B3-induced chronic myocarditis in mice. The favorable pharmacokinetic, toxicological, and pharmacodynamics profile in mice renders OBR-5-340 a highly promising drug candidate, and the regulatory nonclinical program is ongoing.
17
Activity of Pleconaril against Enteroviruses
Daniel C. Pevear, T.M. Tull, Martin E. Seipel et al. · Antimicrobial Agents and Chemotherapy · 1999 · 369 citations · Full text
The structure of coxsackievirus B3 at 3.5 å resolution
J.K. Muckelbauer, Marcia J. Kremer, Iwona Minor et al. · Structure · 1995 · 280 citations